Analysis of the efficacy of different amounts of parathyroid grafts in the treatment of secondary hyperparathyroidism

被引:0
作者
Chen, Wentan [1 ]
Zhou, Ge [2 ]
机构
[1] China Med Univ, Liaoyang Cent Hosp, Dept Gen Surg, Postgrad Training Base, Liaoyang 111000, Peoples R China
[2] Liaoyang Cent Hosp, Dept Gen Surg, Liaoyang, Peoples R China
关键词
Secondary hyperparathyroidism; Chronic kidney disease; Total parathyroidectomy; Parathyroid hormone; Autotransplantation; SURGICAL-MANAGEMENT; DIALYSIS PATIENTS; CINACALCET; BONE;
D O I
10.1186/s12902-024-01777-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeThis study compares the efficacy of two different ranges of parathyroid transplantation weights with the aim of determining a preferable range for transplantation weight.MethodsFrom May 2018 to June 2023, 79 patients underwent total parathyroidectomy with autotransplantation. Demographic data, symptoms, and pre- or postoperative biochemical indicators were compared between two different ranges of parathyroid transplantation weights.ResultsAll 79 surgeries were successful, with a total of 316 parathyroid glands reported among the patients. The patients were diagnosed with parathyroid hyperplasia. Postoperatively, itching, bone pain, and muscle weakness disappeared, while serum parathyroid hormone and phosphate levels significantly decreased. With an average follow-up of 12 months, no transplant-dependent recurrence was observed.ConclusionParathyroid transplantation with a weight of 30-50 mg is a feasible, safe, and effective surgical approach.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Achieving therapeutic targets in the treatment of secondary hyperparathyroidism
    Cunningham, J
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 : 9 - 14
  • [42] Relationship between Reductions in Parathyroid Hormone and Serum Phosphorus during the Management of Secondary Hyperparathyroidism with Calcimimetics in Hemodialysis Patients
    Cooper, Kerry
    Quarles, Darryl
    Kubo, Yumi
    Tomlin, Holly
    Goodman, William
    NEPHRON CLINICAL PRACTICE, 2012, 121 (3-4): : C124 - C130
  • [43] Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis
    Diao, Zongli
    Liu, Xu
    Qian, Linxue
    Liu, Jing
    Liu, Sha
    Liu, Wenhu
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2016, 32 (06) : 614 - 622
  • [44] Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis
    Wang, Zhizhou
    Wang, Yexuan
    Han, Shun
    Chen, Peixian
    Wu, Ruo
    Fang, Chuyao
    Cheng, Junjie
    Wu, Yujiao
    Guo, Tingting
    Wen, Xin
    Li, Lujin
    JOURNAL OF THE ENDOCRINE SOCIETY, 2025, 9 (05)
  • [45] A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients
    Bell, Gregory
    Huang, Saling
    Martin, Kevin J.
    Block, Geoffrey A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (05) : 943 - 952
  • [46] Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism
    Morii, H
    Ogura, Y
    Koshikawa, S
    Mimura, N
    Suzuki, M
    Kurokawa, K
    Marumo, F
    Kawaguchi, Y
    Maeda, K
    Nishizawa, Y
    Inoue, S
    Fujimi, S
    JOURNAL OF BONE AND MINERAL METABOLISM, 1998, 16 (01) : 34 - 43
  • [47] Efficacy of Radiofrequency Ablation/Microwave Ablation Technology for Treatment of Chronic Kidney Disease Complicated with Secondary Hyperparathyroidism
    Liu, Xueping
    Zhou, Yuwang
    Liu, Chunya
    Liu, Xianglan
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2022, 19 (08) : 1477 - 1485
  • [48] The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
    Tabibzadeh, Nahid
    Karaboyas, Angelo
    Robinson, Bruce M.
    Csomor, Philipp A.
    Spiegel, David M.
    Evenepoel, Pieter
    Jacobson, Stefan H.
    Urena-Torres, Pablo-Antonio
    Fukagawa, Masafumi
    Al Salmi, Issa
    Liang, Xinling
    Pisoni, Ronald L.
    Young, Eric W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (01) : 160 - 169
  • [49] Doxercalciferol treatment of secondary hyperparathyroidism
    Dennis, Vincent C.
    Albertson, Guy L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (11) : 1955 - 1965
  • [50] AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients
    Martin, Kevin J.
    Pickthorn, Karen
    Huang, Saling
    Block, Geoffrey A.
    Vick, Andrew
    Mount, Peter F.
    Power, David A.
    Bell, Gregory
    KIDNEY INTERNATIONAL, 2014, 85 (01) : 191 - 197